Procter & Gamble Company (The)

Analyst Ratings Synthesis

The supplied consensus is Hold across 23 analysts, with a mean target of $162; low and high targets were not provided, so the target cluster and full spread cannot be established. Named target evidence ranges from Bernstein’s $156 target to JPMorgan’s $162 target, while an unattributed TipRanks page cites $172 and therefore cannot identify the most bullish analyst. No attributable rating or target revision during the week was supplied. The latest identified revision was JPMorgan’s earlier reduction from $164 to $162 on July 17. The substantive disagreement is whether innovation, productivity and market-share gains can reverse flat organic sales and consumer pricing resistance, or merely cushion a prolonged low-growth period.

• Procter & Gamble To Buy Health Firm Thorne From L Catterton For $3.8 Bln Cash
• Worried About the Market? Hide Out in These 3 High-Yielding Dividend Stocks
• Why the "Magnificent Seven" Trade Is Starting to Fracture, and Where You Should Invest Instead
• SPY, PG, HD, GS: ETF Inflow Alert
• P&G Guided Below Estimates and Sits 5% Above a 52-Week Low. I'm Not Buying It Yet, and Here's What Would Change That.